• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

急性髓系白血病干细胞的耐药机制

Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells.

作者信息

Niu Jialan, Peng Danyue, Liu Lingbo

机构信息

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

出版信息

Front Oncol. 2022 Jul 5;12:896426. doi: 10.3389/fonc.2022.896426. eCollection 2022.

DOI:10.3389/fonc.2022.896426
PMID:35865470
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9294245/
Abstract

Acute myeloid leukemia (AML) is a polyclonal and heterogeneous hematological malignancy. Relapse and refractory after induction chemotherapy are still challenges for curing AML. Leukemia stem cells (LSCs), accepted to originate from hematopoietic stem/precursor cells, are the main root of leukemogenesis and drug resistance. LSCs are dynamic derivations and possess various elusive resistance mechanisms. In this review, we summarized different primary resistance and remolding mechanisms of LSCs after chemotherapy, as well as the indispensable role of the bone marrow microenvironment on LSCs resistance. Through a detailed and comprehensive review of the spectacle of LSCs resistance, it can provide better strategies for future researches on eradicating LSCs and clinical treatment of AML.

摘要

急性髓系白血病（AML）是一种多克隆性和异质性血液系统恶性肿瘤。诱导化疗后的复发和难治性仍然是治愈AML的挑战。白血病干细胞（LSCs）被认为起源于造血干/祖细胞，是白血病发生和耐药的主要根源。LSCs是动态衍生细胞，具有多种难以捉摸的耐药机制。在本综述中，我们总结了化疗后LSCs的不同原发性耐药和重塑机制，以及骨髓微环境对LSCs耐药的不可或缺作用。通过对LSCs耐药现象进行详细而全面的综述，可为未来根除LSCs的研究和AML的临床治疗提供更好的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7b0/9294245/954feb0e5bee/fonc-12-896426-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7b0/9294245/b57edf8ed5d3/fonc-12-896426-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7b0/9294245/e4108475e866/fonc-12-896426-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7b0/9294245/ea158e1bb357/fonc-12-896426-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7b0/9294245/fe286c75fa70/fonc-12-896426-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7b0/9294245/85ef797e80c5/fonc-12-896426-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7b0/9294245/267a7d4c18ed/fonc-12-896426-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7b0/9294245/954feb0e5bee/fonc-12-896426-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7b0/9294245/b57edf8ed5d3/fonc-12-896426-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7b0/9294245/e4108475e866/fonc-12-896426-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7b0/9294245/ea158e1bb357/fonc-12-896426-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7b0/9294245/fe286c75fa70/fonc-12-896426-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7b0/9294245/85ef797e80c5/fonc-12-896426-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7b0/9294245/267a7d4c18ed/fonc-12-896426-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7b0/9294245/954feb0e5bee/fonc-12-896426-g007.jpg

相似文献

1
Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells.急性髓系白血病干细胞的耐药机制
Front Oncol. 2022 Jul 5;12:896426. doi: 10.3389/fonc.2022.896426. eCollection 2022.
2
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development.急性髓系白血病发展过程中白血病干细胞与骨髓微环境的相互作用
Exp Hematol Oncol. 2021 Jul 10;10(1):39. doi: 10.1186/s40164-021-00233-2.
3
Cellular and Molecular State of Myeloid Leukemia Stem Cells.髓系白血病干细胞的细胞和分子状态。
Adv Exp Med Biol. 2019;1143:41-57. doi: 10.1007/978-981-13-7342-8_2.
4
The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting.急性髓系白血病干细胞在微环境中的起源与演变：从生物学特性到治疗靶点
Cell Death Discov. 2022 Sep 26;8(1):397. doi: 10.1038/s41420-022-01193-0.
5
Therapeutic targeting of leukemia stem cells in acute myeloid leukemia.急性髓系白血病中白血病干细胞的治疗靶点
Front Oncol. 2023 Aug 3;13:1204895. doi: 10.3389/fonc.2023.1204895. eCollection 2023.
6
Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia.逃避治疗：急性髓系白血病中白血病干细胞的不同面貌与治疗抗性
Front Oncol. 2021 May 3;11:659253. doi: 10.3389/fonc.2021.659253. eCollection 2021.
7
CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia.CD9，一种潜在的白血病干细胞标志物，调节急性髓系白血病中的耐药性和白血病发展。
Stem Cell Res Ther. 2021 Jan 25;12(1):86. doi: 10.1186/s13287-021-02155-6.
8
Targeting acute myeloid leukemia stem cell signaling by natural products.天然产物靶向急性髓系白血病干细胞信号通路
Mol Cancer. 2017 Jan 30;16(1):13. doi: 10.1186/s12943-016-0571-x.
9
Clinical roles of TIM-3 in myeloid malignancies and its importance in cellular therapy.TIM-3在髓系恶性肿瘤中的临床作用及其在细胞治疗中的重要性。
Blood Cell Ther. 2022 Dec 23;5(Spec Edition):S1-S5. doi: 10.31547/bct-2022-010.
10
Lipids and the cancer stemness regulatory system in acute myeloid leukemia.急性髓系白血病中的脂质与癌症干细胞调控系统。
Essays Biochem. 2022 Sep 16;66(4):333-344. doi: 10.1042/EBC20220028.

引用本文的文献

1
TLR7/8 ligands R848 and imiquimod induce differentiation of bone marrow cells from patients with myelodysplastic syndrome towards mature neutrophils.Toll样受体7/8（TLR7/8）配体R848和咪喹莫特可诱导骨髓增生异常综合征患者的骨髓细胞向成熟中性粒细胞分化。
Sci Rep. 2025 Aug 26;15(1):31496. doi: 10.1038/s41598-025-15859-z.
2
Generalized information criteria for personalized gene network inference.用于个性化基因网络推断的广义信息准则。
Front Genet. 2025 Jun 20;16:1583756. doi: 10.3389/fgene.2025.1583756. eCollection 2025.
3
"Galectin-9: A double-edged sword in Acute Myeloid Leukemia".

本文引用的文献

1
Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.通过抑制 PI3K/AKT/mTOR 通路联合全反式维甲酸治疗急性髓系白血病以获得治疗增益，抑制 MYC。
Br J Haematol. 2022 Jul;198(2):338-348. doi: 10.1111/bjh.18187. Epub 2022 Apr 25.
2
Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment.靶向赖氨酸特异性去甲基化酶 1 可重塑激酶网络并使白血病细胞对激酶抑制剂治疗敏感。
Sci Signal. 2022 Apr 19;15(730):eabl7989. doi: 10.1126/scisignal.abl7989.
3
Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance.
半乳糖凝集素-9：急性髓系白血病中的一把双刃剑
Ann Hematol. 2025 May 9. doi: 10.1007/s00277-025-06387-x.
4
Therapeutic hurdles in acute myeloid leukemia: Leukemic stem cells, inflammation and immune dysfunction.急性髓系白血病的治疗障碍：白血病干细胞、炎症与免疫功能障碍。
Curr Opin Pharmacol. 2025 Jun;82:102526. doi: 10.1016/j.coph.2025.102526. Epub 2025 Apr 8.
5
Learning the therapeutic targets of acute myeloid leukemia through multiscale human interactome network and community analysis.通过多尺度人类相互作用组网络和群落分析了解急性髓系白血病的治疗靶点。
BioData Min. 2025 May 2;18(1):32. doi: 10.1186/s13040-025-00444-x.
6
Bone marrow immune cells and drug resistance in acute myeloid leukemia.急性髓系白血病中的骨髓免疫细胞与耐药性
Exp Biol Med (Maywood). 2025 Feb 11;250:10235. doi: 10.3389/ebm.2025.10235. eCollection 2025.
7
The mitochondria as an emerging target of self-renewal in T-cell acute lymphoblastic leukemia.线粒体作为T细胞急性淋巴细胞白血病自我更新的一个新靶点。
Cancer Biol Ther. 2025 Dec;26(1):2460252. doi: 10.1080/15384047.2025.2460252. Epub 2025 Feb 4.
8
Mitochondrial abnormalities as a target of intervention in acute myeloid leukemia.线粒体异常作为急性髓系白血病的干预靶点
Front Oncol. 2025 Jan 20;14:1532857. doi: 10.3389/fonc.2024.1532857. eCollection 2024.
9
The Role of Chronic Inflammation in Pediatric Cancer.慢性炎症在儿童癌症中的作用。
Cancers (Basel). 2025 Jan 6;17(1):154. doi: 10.3390/cancers17010154.
10
Nootkatone Derivative Nootkatone-(E)-2-iodobenzoyl hydrazone Promotes Megakaryocytic Differentiation in Erythroleukemia by Targeting JAK2 and Enhancing JAK2/STAT3 and PKCδ/MAPK Crosstalk.诺卡酮衍生物诺卡酮-(E)-2-碘苯甲酰腙通过靶向JAK2并增强JAK2/STAT3和PKCδ/MAPK信号通路间的相互作用促进红白血病中巨核细胞的分化。
Cells. 2024 Dec 26;14(1):10. doi: 10.3390/cells14010010.
维奈托克在急性髓系白血病中的应用：分子基础、临床前及临床疗效证据以及靶向耐药的策略
Cancers (Basel). 2021 Nov 9;13(22):5608. doi: 10.3390/cancers13225608.
4
Treatment Failure in Acute Myeloid Leukemia: Focus on the Role of Extracellular Vesicles.急性髓系白血病治疗失败：关注细胞外囊泡的作用。
Leuk Res. 2022 Jan;112:106751. doi: 10.1016/j.leukres.2021.106751. Epub 2021 Nov 16.
5
Loss of MBD2 attenuates MLL-AF9-driven leukemogenesis by suppressing the leukemic cell cycle via CDKN1C.MBD2的缺失通过CDKN1C抑制白血病细胞周期，从而减弱MLL-AF9驱动的白血病发生。
Oncogenesis. 2021 Nov 17;10(11):79. doi: 10.1038/s41389-021-00366-3.
6
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.依尼西尼（enasidenib）联合阿扎胞苷对比阿扎胞苷单药治疗新诊断、突变型 IDH2 急性髓系白血病患者（AG221-AML-005）：一项单臂、1b 期和随机、2 期试验。
Lancet Oncol. 2021 Nov;22(11):1597-1608. doi: 10.1016/S1470-2045(21)00494-0. Epub 2021 Oct 18.
7
Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia.Hedgehog 通路抑制剂：急性髓系白血病治疗的新治疗类别。
Blood Cancer Discov. 2020 Aug 11;1(2):134-145. doi: 10.1158/2643-3230.BCD-20-0007. eCollection 2020 Sep.
8
Recreating the Bone Marrow Microenvironment to Model Leukemic Stem Cell Quiescence.重建骨髓微环境以模拟白血病干细胞的静止状态。
Front Cell Dev Biol. 2021 Sep 13;9:662868. doi: 10.3389/fcell.2021.662868. eCollection 2021.
9
BH3 Mimetics in Hematologic Malignancies.BH3 模拟物在血液系统恶性肿瘤中的应用。
Int J Mol Sci. 2021 Sep 21;22(18):10157. doi: 10.3390/ijms221810157.
10
Roles of Histone Deacetylases in Acute Myeloid Leukemia With Fusion Proteins.组蛋白去乙酰化酶在伴有融合蛋白的急性髓系白血病中的作用
Front Oncol. 2021 Sep 1;11:741746. doi: 10.3389/fonc.2021.741746. eCollection 2021.